Canagliflozin vs Zibotentan + Dapagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline
Canagliflozin · Invokana
Marketed by Johnson & Johnson and partners
NCT02065791 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 4,401 participants with type 2 diabetes and diabetic nephropathy. Canagliflozin significantly lowered the rate of the composite renal/cardiovascular endpoint (kidney failure, doubling of creatinine, or renal/CV death) compared with placebo, with a hazard ratio of 0.70.
Next expected readout: December 2026 · NCT05507892 (registry estimate)
Reported efficacy
Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029) (met)
Result source: NCT03436693
Zibotentan + Dapagliflozin
Developed by AstraZeneca
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT06087835 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Canagliflozin | Zibotentan + Dapagliflozin |
|---|---|---|
| Kidney composite outcome | —Not reported | —Trial running · NCT06087835 |
| UACR, % change | 0.6% vs 1.2%−0.6 vs placeboNCT03436693 | —Trial running · NCT06087835 |
| eGFR slope | —Not reported | —Trial running · NCT06087835 |
| Haemoglobin, change | —Not reported | —Trial running · NCT06087835 |
Kidney composite outcome
- Canagliflozin
- —Not reported
- Zibotentan + Dapagliflozin
- —Trial running · NCT06087835
UACR, % change
- Canagliflozin
- 0.6% vs 1.2%−0.6 vs placeboNCT03436693
- Zibotentan + Dapagliflozin
- —Trial running · NCT06087835
eGFR slope
- Canagliflozin
- —Not reported
- Zibotentan + Dapagliflozin
- —Trial running · NCT06087835
Haemoglobin, change
- Canagliflozin
- —Not reported
- Zibotentan + Dapagliflozin
- —Trial running · NCT06087835
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Zibotentan + Dapagliflozin: registry results are on file for Chronic Kidney Disease, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Canagliflozin: 4 of 4 rows · Zibotentan + Dapagliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Canagliflozin |
|---|---|
| Dropout rate | 0.7%100 mga NCT02065791 · Phase 3 show 1 more result19.5%100mg NCT03436693 · Phase 3 |
| Discontinued due to AEs | —100 mga NCT02065791 · Phase 3 show 1 more result14.3%100mg NCT03436693 · Phase 3 |
| Serious AEs | 33.5%100 mga NCT02065791 · Phase 3 show 1 more result27.9%100mg NCT03436693 · Phase 3 |
| Most frequent reported AEs | 100 mga hypoglycaemia 9.7% (placebo 10.3%) urinary tract infection 9.2% (placebo 8.4%) hypertension 6.5% (placebo 8.8%) NCT02065791 · Phase 3 show 1 more result100mg nasopharyngitis 35.1% (placebo 37%) hypoglycaemia 21.4% (placebo 20.8%) blood glucose decreased 17.5% (placebo 14.9%) NCT03436693 · Phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Canagliflozin
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Canagliflozin's landscape · Zibotentan + Dapagliflozin's landscape